Highlights
SEC in CDSCO on Wednesday did not grant EUA to COVID-19 vaccine developed by Oxford-AstraZeneca for use in India.
The SEC also refused to consider the EUA request of Pfizer and Bharat Biotech Pvt Limited.
The SEC is scheduled to meet again on January 1 to hold discussions over this matter.
In a significant development, the Subject Expert Committee (SEC) in Central Drugs Standard Control Organisation (CDSCO) on Wednesday (December 30) did not grant EUA to COVID-19 vaccine developed by Oxford-AstraZeneca for use in India. The SEC also refused to consider the Emergency Use Authorisation (EUA) request of Pfizer and Bharat Biotech Pvt Limited saying that vaccines developed by all these companies will not be given authorisation “yet” as more data is needed.